# Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

> **NCT03546829** · PHASE1 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Early Stage Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Vancomycin
- **RADIATION:** Precision hypofractionated radiation

## Key facts

- **NCT ID:** NCT03546829
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-03-05
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546829, "Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03546829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*